Physician profile
Micah A Jacobs
NPI 1386845022
$205,641.48
in general payments reported to CMS, 2019-2025
23 companies · $7,558 in 2025
The $7,558 reported for 2025 was more than what 92% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66K · 2020: $30K · 2021: $31K · 2022: $25K · 2023: $13K · 2024: $32K · 2025: $7,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $45K · Food and Beverage: $5,109 · Travel and Lodging: $2,245 · Consulting Fee: $450 · Education: $324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $44,815.34 |
| Food and Beverage | $5,108.76 |
| Travel and Lodging | $2,244.74 |
| Consulting Fee | $450.00 |
| Education | $323.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $70,796.20 | 2021-2025 | |
| Allergan, INC. | $68,266.34 | 2019-2021 | |
| Cumberland Pharmaceuticals, INC. | $44,323.18 | 2019-2025 | Vibativ, Caldolor |
| Paratek Pharmaceuticals, INC. | $6,017.01 | 2019-2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $5,862.39 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Insmed, INC. | $5,257.55 | 2019-2025 | Arikayce |
| Invivyd INC | $2,693.04 | 2024-2025 | Pemgarda |
| Astellas Pharma US INC | $632.37 | 2022-2025 | Cresemba |
| Becton, Dickinson and Company | $541.67 | 2022 | |
| Melinta Therapeutics, LLC | $532.46 | 2019-2025 | Rezzayo, Kimyrsa, Vabomere |
| Aimmune Therapeutics, INC. | $168.78 | 2023-2025 | Vowst, Zenpep |
| Shionogi INC | $162.54 | 2022-2024 | Fetroja |
| Tetraphase Pharmaceuticals, INC. | $87.64 | 2019 | |
| Ferring Pharmaceuticals INC. | $87.63 | 2024 | Rebyota |
| Janssen Biotech, INC. | $48.85 | 2023 | Symtuza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $46.25 | 2021-2025 | |
| La Jolla Pharmaceutical Company | $42.50 | 2024-2025 | Zevtera, Xerava |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 | |
| Mayne Pharma Commercial LLC | $15.53 | 2019 | |
| Mylan Specialty L.P. | $14.76 | 2019 | |
| Nabriva Therapeutics, Plc | $14.41 | 2021 | |
| Tactile Systems Technology INC | $14.27 | 2024 | Entre Plus, Flexitouch Plus |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Micah Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.